Citius Oncology Files 8-K Report

Ticker: CTOR · Form: 8-K · Filed: Dec 1, 2025 · CIK: 1851484

Sentiment: neutral

Topics: corporate-disclosure, filing

TL;DR

Citius Oncology filed an 8-K on Dec 1, 2025, covering Reg FD, other events, and financials.

AI Summary

On December 1, 2025, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, along with Financial Statements and Exhibits. The company, formerly known as TenX Keane Acquisition until March 15, 2021, is incorporated in Delaware and headquartered in Cranford, NJ.

Why It Matters

This 8-K filing provides updates on Citius Oncology's corporate activities and financial reporting, which are important for investors to monitor the company's status.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Citius Oncology, Inc.?

The filing is for Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

When was Citius Oncology, Inc. formerly known by another name?

The company was formerly known as TenX Keane Acquisition until March 15, 2021.

Where are Citius Oncology, Inc.'s principal executive offices located?

The principal executive offices are located at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.

What is the Standard Industrial Classification (SIC) code for Citius Oncology, Inc.?

The SIC code is 2834, which corresponds to Pharmaceutical Preparations.

What is the filing date of this Current Report?

The filing date of this Current Report is December 1, 2025.

Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-12-01 17:12:31

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 1, 2025, Citius Oncology, Inc. (the "Company") posted an updated Corporate Presentation on its website. A copy of the Corporate Presentation is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. On December 1, 2025, the Company issued a press release announcing the commercial launch of LYMPHIR (denileukin diftitox-cxdl), a novel IL-2 receptor-directed fusion protein approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation of December 2025 99.2 Press Release, dated December 1, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS ONCOLOGY, INC. Date: December 1, 2025 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing